Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,078,426 shares of the biopharmaceutical company’s stock after buying an additional 63,699 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.77% of Halozyme Therapeutics worth $152,431,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. DLD Asset Management LP acquired a new position in shares of Halozyme Therapeutics during the second quarter worth about $650,250,000. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after acquiring an additional 1,425,674 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Halozyme Therapeutics by 294.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after purchasing an additional 1,082,638 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics in the second quarter valued at approximately $51,295,000. Finally, Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $45,027,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HALO. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $78.56.

Insider Activity

In other news, COO Cortney Caudill sold 20,000 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the completion of the sale, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at $974,014.80. This represents a 58.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at $53,947,690.28. This represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 90,857 shares of company stock worth $6,500,287. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Down 0.5%

Shares of NASDAQ:HALO opened at $67.81 on Wednesday. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The company’s 50-day moving average price is $72.64 and its 200 day moving average price is $70.67. The company has a market cap of $8.00 billion, a PE ratio of 27.23, a P/E/G ratio of 0.28 and a beta of 0.98. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same quarter last year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 51.6% on a year-over-year basis. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.